| Popis: |
Designer benzodiazepines are one of the primary new psychoactive substance (NPS) threats around the world, being found in large numbers in postmortem, driving under the influence of drugs and drug-facilitated sexual assault cases. Even though when compared to many other NPS types, such as opioids and cathinones, there are relatively few designer benzodiazepines being monitored. Recently, a new NPS benzodiazepine has been reported in Europe, the USA and Canada, desalkygidazepam, also known as bromonordiazepam. This substance is a metabolite of the prodrug gidazepam, a drug licensed for use in Ukraine and Russia under the name Gidazepam IC®. In the paper, we review what is currently known about the use, pharmacology and analytical detection of gidazepam, its metabolite desalkygidazepam and their other possible metabolites. |
